CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx, Inc. (CDNA)
Last caredx, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.caredxinc.com
Company Research
Source: Business Wire
Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ETInvestor webcast will feature the clinical validation data and review commercial launch timeline BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 4-7, 2026, in Salt Lake City, Utah.The ACROBAT study is a prospective, multi-center, blinded clinical trial evaluating AlloHeme, CareDx’s AI-powered next-generation sequencing (NGS)-based peripheral blood test for monitoring relapse after allogeneic hematopoietic cell transplantation (HCT) in pat
Show less
Read more
Impact Snapshot
Event Time:
CDNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDNA alerts
High impacting CareDx, Inc. news events
Weekly update
A roundup of the hottest topics
CDNA
News
- CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings [Yahoo! Finance]Yahoo! Finance
- CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 [Yahoo! Finance]Yahoo! Finance
- Did Strong 2025 Revenue Growth and 10x Genomics Deal Just Shift CareDx's (CDNA) Investment Narrative? [Yahoo! Finance]Yahoo! Finance
- CareDx President and CEO Sells 19,000 Shares for $412,000 [Yahoo! Finance]Yahoo! Finance
- CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference [Yahoo! Finance]Yahoo! Finance
CDNA
Earnings
- 11/4/25 - Beat
CDNA
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- CDNA's page on the SEC website